A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

• Status: Completed
• Trial end date: 2015-03-20
• Target enrollment: 0
• Participant gender: All

Summary

This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Desvenlafaxine Succinate; Fluoxetine

Criteria

Inclusion Criteria:

• Age >=7 and <18 years of age

• Primary diagnosis of major depressive disorder (MDD)

• CDRS-R score >40

Exclusion Criteria:

• History of suicidal behaviour, or requires precaution against suicide

• Not in generally healthy medical condition

• History of psychosis or bipolar disorder

• Seizure disorder